Cargando…

Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies

3D cell culture including different cell types, such as immune cells, is a representative platform that mimics the tumor microenvironment. Here we disclose an easy-to-handle 3D co-culture protocol using a scaffold-free technique with the breast cancer cell line MDA-MB-231 and breast cancer patient-d...

Descripción completa

Detalles Bibliográficos
Autores principales: Saraiva, Diana P., Matias, Ana T., Braga, Sofia, Jacinto, António, Cabral, M. Guadalupe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482668/
https://www.ncbi.nlm.nih.gov/pubmed/32974189
http://dx.doi.org/10.3389/fonc.2020.01543
_version_ 1783580831432835072
author Saraiva, Diana P.
Matias, Ana T.
Braga, Sofia
Jacinto, António
Cabral, M. Guadalupe
author_facet Saraiva, Diana P.
Matias, Ana T.
Braga, Sofia
Jacinto, António
Cabral, M. Guadalupe
author_sort Saraiva, Diana P.
collection PubMed
description 3D cell culture including different cell types, such as immune cells, is a representative platform that mimics the tumor microenvironment. Here we disclose an easy-to-handle 3D co-culture protocol using a scaffold-free technique with the breast cancer cell line MDA-MB-231 and breast cancer patient-derived immune cells from peripheral blood. The method presented is simple, less time-consuming and less expensive when compared to other 3D techniques. Additionally, this is an optimized protocol for the establishment of a 3D system for this cell line, which is normally seen as challenging to spontaneously form spheroids. The addition of patient-derived immune cells to the cancer cells' spheroid allows the study of the crosstalk between both cell types, as well as the assessment of individual therapeutic approaches to intensify the antitumor immune response. In fact, with this model, we observed that patients' immune cells exhibit a wide range of antitumor responses and we further demonstrated that it is possible to manipulate the less effective ones with a canonical stimulus, as a proof-of-concept, in order to improve their ability to lower the viability of tumor cells. Therefore, this platform could be applied for a personalized immune-based drug screening, with results after a maximum of 10 days of culture, in order to develop more tailored breast cancer treatments and ameliorate patients' survival rate.
format Online
Article
Text
id pubmed-7482668
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74826682020-09-23 Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies Saraiva, Diana P. Matias, Ana T. Braga, Sofia Jacinto, António Cabral, M. Guadalupe Front Oncol Oncology 3D cell culture including different cell types, such as immune cells, is a representative platform that mimics the tumor microenvironment. Here we disclose an easy-to-handle 3D co-culture protocol using a scaffold-free technique with the breast cancer cell line MDA-MB-231 and breast cancer patient-derived immune cells from peripheral blood. The method presented is simple, less time-consuming and less expensive when compared to other 3D techniques. Additionally, this is an optimized protocol for the establishment of a 3D system for this cell line, which is normally seen as challenging to spontaneously form spheroids. The addition of patient-derived immune cells to the cancer cells' spheroid allows the study of the crosstalk between both cell types, as well as the assessment of individual therapeutic approaches to intensify the antitumor immune response. In fact, with this model, we observed that patients' immune cells exhibit a wide range of antitumor responses and we further demonstrated that it is possible to manipulate the less effective ones with a canonical stimulus, as a proof-of-concept, in order to improve their ability to lower the viability of tumor cells. Therefore, this platform could be applied for a personalized immune-based drug screening, with results after a maximum of 10 days of culture, in order to develop more tailored breast cancer treatments and ameliorate patients' survival rate. Frontiers Media S.A. 2020-08-27 /pmc/articles/PMC7482668/ /pubmed/32974189 http://dx.doi.org/10.3389/fonc.2020.01543 Text en Copyright © 2020 Saraiva, Matias, Braga, Jacinto and Cabral. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Saraiva, Diana P.
Matias, Ana T.
Braga, Sofia
Jacinto, António
Cabral, M. Guadalupe
Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies
title Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies
title_full Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies
title_fullStr Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies
title_full_unstemmed Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies
title_short Establishment of a 3D Co-culture With MDA-MB-231 Breast Cancer Cell Line and Patient-Derived Immune Cells for Application in the Development of Immunotherapies
title_sort establishment of a 3d co-culture with mda-mb-231 breast cancer cell line and patient-derived immune cells for application in the development of immunotherapies
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482668/
https://www.ncbi.nlm.nih.gov/pubmed/32974189
http://dx.doi.org/10.3389/fonc.2020.01543
work_keys_str_mv AT saraivadianap establishmentofa3dcoculturewithmdamb231breastcancercelllineandpatientderivedimmunecellsforapplicationinthedevelopmentofimmunotherapies
AT matiasanat establishmentofa3dcoculturewithmdamb231breastcancercelllineandpatientderivedimmunecellsforapplicationinthedevelopmentofimmunotherapies
AT bragasofia establishmentofa3dcoculturewithmdamb231breastcancercelllineandpatientderivedimmunecellsforapplicationinthedevelopmentofimmunotherapies
AT jacintoantonio establishmentofa3dcoculturewithmdamb231breastcancercelllineandpatientderivedimmunecellsforapplicationinthedevelopmentofimmunotherapies
AT cabralmguadalupe establishmentofa3dcoculturewithmdamb231breastcancercelllineandpatientderivedimmunecellsforapplicationinthedevelopmentofimmunotherapies